地拉罗司分散片图片

Deferasirox (Enrige) is used for patients with iron accumulation due to long-term blood transfusion (such as thalassemia or other rare anemias). It is suitable for children over two years old and adults. Deferasirox (Enrego) is an iron chelator product developed by the Swiss pharmaceutical company Novartis. It is the first oral iron anthelmintic approved by the US FDA for routine use.

At present, Deferasirox (Enrego) has also been launched in China. The domestic specification of Deferasirox (Enrego) is 125mg/tablet*28 tablets/bottle (box), and the price is 2330$, which is not cheap. Although it has been marketed in China, it is not included in the medical insurance catalog, so patients cannot be reimbursed by medical insurance after purchasing the drug. If patients need to take this drug for long-term treatment, the price will be a big burden.

CIPLA Pharmaceuticals, one of the well-known pharmaceutical companies in India, has launched a generic version of Deferasirox (Enrega), with a specification of 500mg*30 tablets/box and a price equivalent to RMB only about $500. The price is much lower than that of the original drug. Although it is a generic drug, its efficacy is almost the same as that of the original drug, and the price-performance ratio is high. Since the exchange rate is not fixed, if the price is not fixed, if patients want to know the specific price of the drug, or if they want to purchase Deferasirox (Enrige) overseas, they can consult with domestic reliable overseas medical service institutions (such as Medical Companion Travel).

The therapeutic effect of Deferasirox (Enrig) is significant, but patients cannot blindly take this drug for treatment. Taking Deferasirox (Enrig) will also produce certain side effects or adverse reactions. The most common adverse reactions include: diarrhea/vomiting/headache/abdominal pain/fever/rash/increased serum creatinine, etc. Patients should undergo detailed examination before receiving deferasirox (Enrige) treatment and strictly follow the doctor's diagnosis and treatment recommendations.

The above is the introduction about Deferasirox (Enrego), I hope it can help everyone. If patients have other questions about the drug, they can consult the medical companion service.